FDA Continues To Speed PD-1/L1 Drugs To Market
The four-month review of Merck’s Keytruda for first-line lung cancer is a reminder of how quickly the agency has acted on the immune checkpoint inhibitors.
The four-month review of Merck’s Keytruda for first-line lung cancer is a reminder of how quickly the agency has acted on the immune checkpoint inhibitors.